Observational studyScientific reports2026
Oxymatrine regulates SPHKS/S1P signaling pathway in diabetic retinopathy: an observational clinical cohort study.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe SPHKS/S1P pathway has a complex yet close association with the progression of diabetic retinopathy (DR). Oxymatrine (OMT), is believed to potentially regulate this pathway; however, systematic clinical evidence remains insufficient.
methodsA total of 84 DR cases was finally included in the observation cohort, among which 41 cases were assigned to the OMT group and 43 cases to the non-OMT group. Additionally, 20 non-DR cases were included as blank controls. The levels of 4 target proteins, including S1P, VEGF, SPHK1, and SPHK2, were detected in the peripheral blood of cases in each group. The temporal changes in these protein levels were compared between the OMT group and the non-OMT group. Furthermore, the progression of DR between the two groups was statistically analyzed before and after treatment.
resultsCompared with non-DR cases, the levels of 4 target proteins of DR cases were significantly increased. No statistically significant differences in the levels of these proteins were observed between the OMT group and the non-OMT group before treatment; the temporal change trends in the expression levels of these proteins in the OMT group were significantly lower than those in the non-OMT group after treatment. However, no statistically significant differences were found between the OMT group and the non-OMT group in terms of DR progression.
conclusionOMT could inhibit the activity of the SPHKS/S1P pathway and downregulate the expression of key proteins; however, the clinical efficacy of OMT in relieving the progression of DR remained unclear in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.